Organ‐on‐chip models: Implications in drug discovery and clinical applications
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Before a lead compound goes through a clinical trial, preclinical studies utilize two‐dimensional (2D) in vitro models and animal models to study the pharmacodynamics and pharmacokinetics of that lead compound. However, these current preclinical studies may not accurately represent the efficacy and safety of a lead compound in humans, as there has been a high failure rate of drugs that enter clinical trials. All of these failures and the associated costs demonstrate a need for more representative models of human organ systems for screening in the preclinical phase of drug development. In this study, we review the recent advances in in vitro modeling including three‐dimensional (3D) organoids, 3D microfabrication, and 3D bioprinting for various organs including the heart, kidney, lung, gastrointestinal tract (intestine–gut–stomach), liver, placenta, adipose, retina, bone, and brain as well as multiorgan models. The availability of organ‐on‐chip models provides a wealth of opportunities to understand the pathogenesis of human diseases and provide a potentially better model to screen a drug, as these models utilize a dynamic 3D environment similar to the human body. Although there are limitations of organ‐on‐chip models, the emergence of new technologies have refined their capability for translational research as well as precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure
Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., Hammack, C., Yao, B., Hamersky, G. R., Jacob, F., Zhong, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.032 · Cited by 2,127
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“…for genetic diseases such as diabetes or cystic fibrosis, but also to model viral and bacterial infections, host–microbe interactions, as well as models to determine drug effectiveness on colon cancer (Hill & Spence, 2017; Vlachogiannis et al., 2018; Yin et al., 2015; T. Zhou et al., 2017).”
BackgroundLabelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833
Assembly of functionally integrated human forebrain spheroids
Birey, F., Andersen, J., Makinson, C. D., Islam, S., Wei, W., Huber, N., Fan, H. C., Metzler, K. R. C., Panagiotakos, G., Thom, N., et al. (2017) · Nature · doi:10.1038/nature22330 · Cited by 1,365 · cited 1×
“The interneurons derived from hiPSC in vitro in patients with Timothy Syndrome (TS) have been used to identify novel drugs for this neurodevelopmental disease (Birey et al., 2017).”
BackgroundThe Cellular and Molecular Landscapes of the Developing Human Central Nervous System
Silbereis, J. C., Pochareddy, S., Zhu, Y., Li, M., & Sestan, N. (2016) · Neuron · doi:10.1016/j.neuron.2015.12.008 · Cited by 818
Fused cerebral organoids model interactions between brain regions
Bagley, J. A., Reumann, D., Bian, S., Lévi-Strauss, J., & Knoblich, J. A. (2017) · Nature Methods · doi:10.1038/nmeth.4304 · Cited by 790
Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids
Kasendra, M., Tovaglieri, A., Sontheimer-Phelps, A., Jalili-Firoozinezhad, S., Bein, A., Chalkiadaki, A., Scholl, W., Zhang, C., Rickner, H., Richmond, C. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21201-7 · Cited by 754
Three-dimensional organotypic culture: experimental models of mammalian biology and disease
Shamir, E. R., & Ewald, A. J. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3873 · Cited by 719 · cited 1×
“Another way to culture is the mechanically supported culture which allows nutrients from the medium to reach stem cells or slices of large organs (adapted from Shamir and Ewald 2014).”
BackgroundMicrofabrication of human organs-on-chips
Huh, D., Kim, H. J., Fraser, J. P., Shea, D. E., Khan, M., Bahinski, A., Hamilton, G. A., & Ingber, D. E. (2013) · Nature Protocols · doi:10.1038/nprot.2013.137 · Cited by 712 · cited 2×
“PDMS is commonly used in organ miniaturization due to its properties of biocompatibility, is easily molded, and it is transparent (Figure 4) allowing for easy representation with photography (Benam et al., 2017; Huh et al., 2013).”
BackgroundMethod
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
In Vitro Strategies to Vascularize 3D Physiologically Relevant Models
Dellaquila, A., Le Bao, C., Letourneur, D., & Simon‐Yarza, T. (2021) · Advanced Science · doi:10.1002/advs.202100798 · Cited by 115
Alternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“126 For example, Huh et al. generated a lung-on-a-chip model that they comprehensively characterized regarding exposure to bacteria and pro-inflammatory stimuli.”
Background
Metadata
- Authors
- Mittal, R., Woo, F. W., Castro, C. S., Cohen, M. A., Karanxha, J., Mittal, J., Chhibber, T., & Jhaveri, V. M.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-11-15
- Volume
- 234
- Issue
- 6
- Pages
- 8352-8380
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2901737871
- Cited by
- 234
- References
- 24
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.